Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges.
biomarker
immunotherapy
molecular classification
triple negative breast cancer
tumor heterogeneity
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
26 Jan 2023
26 Jan 2023
Historique:
received:
19
12
2022
revised:
20
01
2023
accepted:
22
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
Triple negative breast cancer (TNBC) is a highly heterogeneous disease with a poor prognosis and a paucity of therapeutic options. In recent years, immunotherapy has emerged as a new treatment option for patients with TNBC. However, this therapeutic evolution is paralleled by a growing need for biomarkers which allow for a better selection of patients who are most likely to benefit from this immune checkpoint inhibitor (ICI)-based regimen. These biomarkers will not only facilitate a better optimization of treatment strategies, but they will also avoid unnecessary side effects in non-responders, and limit the increasing financial toxicity linked to the use of these agents. Huge efforts have been deployed to identify predictive biomarkers for the ICI, but until now, the fruits of this labor remained largely unsatisfactory. Among clinically validated biomarkers, only programmed death-ligand 1 protein (PD-L1) expression has been prospectively assessed in TNBC trials. In addition to this, microsatellite instability and a high tumor mutational burden are approved as tumor agnostic biomarkers, but only a small percentage of TNBC fits this category. Furthermore, TNBC should no longer be approached as a single biological entity, but rather as a complex disease with different molecular, clinicopathological, and tumor microenvironment subgroups. This review provides an overview of the validated and evolving predictive biomarkers for a response to ICI in TNBC.
Identifiants
pubmed: 36769602
pii: jcm12030953
doi: 10.3390/jcm12030953
pmc: PMC9917763
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cancer Res. 1998 Nov 15;58(22):5248-57
pubmed: 9823339
Ann Oncol. 2018 Apr 1;29(4):895-902
pubmed: 29365031
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Breast Cancer Res Treat. 2020 Jun;181(3):553-560
pubmed: 32358635
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Nature. 2020 Feb;578(7796):615-620
pubmed: 31959985
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
J Natl Cancer Inst. 2021 Aug 2;113(8):1005-1016
pubmed: 33523233
Front Immunol. 2021 Feb 24;12:561793
pubmed: 33717059
Ann Oncol. 2018 Nov 1;29(11):2232-2239
pubmed: 30203045
J Pathol. 2020 Apr;250(5):667-684
pubmed: 32129476
Breast Cancer Res. 2020 Jan 28;22(1):12
pubmed: 31992350
Oncoimmunology. 2016 Dec 14;6(1):e1257452
pubmed: 28197375
J Exp Clin Cancer Res. 2018 Dec 29;37(1):327
pubmed: 30594216
Oncologist. 2020 Oct;25(10):e1481-e1491
pubmed: 32406563
Semin Cancer Biol. 2018 Oct;52(Pt 2):151-157
pubmed: 29990622
Clin Cancer Res. 2008 Aug 15;14(16):5158-65
pubmed: 18698033
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
Nat Rev Clin Oncol. 2022 Feb;19(2):91-113
pubmed: 34754128
Nat Rev Clin Oncol. 2021 Jun;18(6):345-362
pubmed: 33580222
Genome Med. 2021 Apr 16;13(1):60
pubmed: 33863341
J Clin Invest. 2019 Apr 1;129(4):1785-1800
pubmed: 30753167
Semin Cancer Biol. 2018 Oct;52(Pt 2):178-188
pubmed: 29104025
Oncologist. 2022 Apr 5;27(4):e313-e327
pubmed: 35380716
Ann Oncol. 2020 Sep;31(9):1115-1118
pubmed: 32771306
Cancer Cell. 2019 Mar 18;35(3):428-440.e5
pubmed: 30853353
Front Microbiol. 2018 May 15;9:951
pubmed: 29867857
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
NPJ Breast Cancer. 2020 May 12;6:16
pubmed: 32411818
Cell Res. 2021 Feb;31(2):178-186
pubmed: 32719455
Nat Med. 2019 Jun;25(6):920-928
pubmed: 31086347
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
Ann Oncol. 2021 May;32(5):661-672
pubmed: 33736924
Clin Cancer Res. 2021 May 1;27(9):2584-2591
pubmed: 33593886
Expert Opin Biol Ther. 2022 Mar;22(3):345-348
pubmed: 34930070
JCI Insight. 2020 Dec 3;5(23):
pubmed: 33268597
Hum Pathol. 2013 Oct;44(10):2055-63
pubmed: 23701942
Sci Transl Med. 2016 Apr 13;8(334):334ra53
pubmed: 27075627
N Engl J Med. 2022 Feb 10;386(6):556-567
pubmed: 35139274
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Science. 2021 Dec 24;374(6575):1632-1640
pubmed: 34941392
N Engl J Med. 2022 Jul 21;387(3):217-226
pubmed: 35857659
Oncologist. 2021 Mar;26(3):e382-e393
pubmed: 33098195
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
Nat Cancer. 2020 Sep;1(9):873-881
pubmed: 35121950
Nat Commun. 2021 Sep 27;12(1):5668
pubmed: 34580291
Sci Immunol. 2022 Aug 26;7(74):eabn8390
pubmed: 36026440
Lancet. 2020 Oct 10;396(10257):1090-1100
pubmed: 32966830
NPJ Breast Cancer. 2020 May 12;6:17
pubmed: 32411819
Ann Oncol. 2019 Mar 1;30(3):397-404
pubmed: 30475950
Cancer Treat Rev. 2021 Sep;99:102257
pubmed: 34237488
Breast J. 2020 Dec;26(12):2424-2427
pubmed: 33314356
Nat Med. 2021 May;27(5):820-832
pubmed: 33958794
Mod Pathol. 2016 Oct;29(10):1155-64
pubmed: 27363491
Ann Oncol. 2020 Aug;31(8):978-990
pubmed: 32610166
Ann Oncol. 2020 Sep;31(9):1216-1222
pubmed: 32461104
Cancer Discov. 2021 Nov;11(11):2796-2811
pubmed: 34183353
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
Nat Commun. 2021 Nov 1;12(1):6276
pubmed: 34725325
Lancet Oncol. 2017 Aug;18(8):1009-1021
pubmed: 28694034
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
J Natl Cancer Inst. 2020 Jul 1;112(7):708-719
pubmed: 31665482
Hum Pathol. 2016 Jan;47(1):52-63
pubmed: 26527522
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
Front Oncol. 2021 Mar 04;11:570623
pubmed: 33747906
Cancer Cell. 2022 Jun 13;40(6):609-623.e6
pubmed: 35623341
Cell Rep. 2017 Jan 3;18(1):248-262
pubmed: 28052254
Nat Med. 2021 Feb;27(2):250-255
pubmed: 33462450
Ann Oncol. 2021 Aug;32(8):983-993
pubmed: 34272041
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758
pubmed: 30787022
J Thorac Oncol. 2018 Sep;13(9):1302-1311
pubmed: 29800747
Cancer Cell. 2019 Aug 12;36(2):168-178.e4
pubmed: 31327656
Cancer Cell. 2021 Dec 13;39(12):1578-1593.e8
pubmed: 34653365
Nature. 2012 Apr 04;486(7403):395-9
pubmed: 22495314
Gastroenterology. 2002 Dec;123(6):1804-11
pubmed: 12454837
Ann Oncol. 2019 Aug 1;30(8):1279-1288
pubmed: 31095287
N Engl J Med. 2017 Oct 12;377(15):1409-1412
pubmed: 29020592
Ann Oncol. 2021 Oct;32(10):1236-1244
pubmed: 34311075
JAMA Oncol. 2016 Oct 01;2(10):1354-1360
pubmed: 27355489
Cancer Discov. 2014 Feb;4(2):232-45
pubmed: 24356096
Science. 2016 May 6;352(6286):658-60
pubmed: 27151852
AAPS J. 2021 Mar 7;23(2):39
pubmed: 33677681
Ann Oncol. 2020 Mar;31(3):387-394
pubmed: 32067680
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
N Engl J Med. 2009 Feb 19;360(8):790-800
pubmed: 19228622
EBioMedicine. 2021 Aug;70:103492
pubmed: 34280779
J Clin Oncol. 2021 Aug 1;39(22):2443-2451
pubmed: 33844595
JAMA Oncol. 2019 Jan 1;5(1):74-82
pubmed: 30242306
Nat Rev Clin Oncol. 2016 Apr;13(4):228-41
pubmed: 26667975
NPJ Breast Cancer. 2022 Jan 11;8(1):3
pubmed: 35017545
Ann Oncol. 2019 Mar 1;30(3):405-411
pubmed: 30475947
Oncologist. 2021 Feb;26(2):99-e217
pubmed: 33141975
Cancer Res. 2019 Jul 15;79(14):3662-3675
pubmed: 31064848
Ann Oncol. 2020 Sep;31(9):1112-1114
pubmed: 32771305
Sci Rep. 2020 Oct 2;10(1):16386
pubmed: 33009475
Clin Cancer Res. 2017 Jul 15;23(14):3585-3591
pubmed: 28073845
Nat Med. 2016 Nov;22(11):1342-1350
pubmed: 27694933
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
J Natl Cancer Inst. 2021 Nov 29;113(12):1733-1743
pubmed: 34097070
JCO Precis Oncol. 2022 Mar;6:e2000368
pubmed: 35294223
Clin Cancer Res. 2019 Aug 15;25(16):5002-5014
pubmed: 30837276
Nat Commun. 2021 Oct 14;12(1):6012
pubmed: 34650042